MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition via TGFβ1/Smad2 signaling pathway in human bladder cancer

References

• Wu J, Wang J. HMGN5 expression in bladder cancer tissue and its role on prognosis. Eur Rev Med Pharmacol Sci. 2018;22(4):970–975. doi:10.26355/eurrev_201802_1437829509244
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL, Dahiya R. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis. 2012;33(1):41–48. doi:10.1093/carcin/bgr23922049531
   PubMed Web of Science ®Google Scholar
• Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219–3227. doi:10.1002/cncr.2814723737352
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11–e79. doi:10.1373/clinchem.2008.10560119042984
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(Suppl 6A):4–34. doi:10.1016/j.urology.2005.07.06216399414
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442. doi:10.1016/j.eururo.2009.06.02819576682
   PubMed Web of Science ®Google Scholar
• Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol. 2000;163(1):68–71.10604316
   PubMed Web of Science ®Google Scholar
• Wu CL, Ho JY, Chou SC, Yu DS. MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 2016;7(18):26593–26603. doi:10.18632/oncotarget.855727058893
   PubMedGoogle Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. doi:10.1016/j.cell.2004.12.03515652477
   PubMed Web of Science ®Google Scholar
• Yu X, Li Z, Shen J, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS One. 2013;8(12):e83080. doi:10.1371/journal.pone.008308024376640
   PubMed Web of Science ®Google Scholar
• Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm Res. 2011;28(12):3043–3049. doi:10.1007/s11095-011-0526-221773853
   PubMed Web of Science ®Google Scholar
• Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 2012;130(11):2526–2538. doi:10.1002/ijc.2625621702042
   PubMed Web of Science ®Google Scholar
• Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol. 2012;19(Suppl 3):S656–S664. doi:10.1245/s10434-012-2217-622311119
   PubMedGoogle Scholar
• Zhang X, Hu S, Zhang X, et al. MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2014;443(3):1078–1084. doi:10.1016/j.bbrc.2013.12.09524370822
   PubMed Web of Science ®Google Scholar
• Huber RM, Rajski M, Sivasankaran B, Moncayo G, Hemmings BA, Merlo A. Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival. PLoS One. 2013;8(2):e57793. doi:10.1371/journal.pone.005779323451269
   PubMed Web of Science ®Google Scholar
• Tian T, Hou L, Xiong YM, et al. miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells. Am J Transl Res. 2016;8(3):1492–1501.27186275
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang J, He J, Zhou W, Xiang G, Xu R. MicroRNA-132 cause apoptosis of glioma cells through blockade of the SREBP-1c metabolic pathway related to SIRT1. Biomed Pharmacother. 2016;78:177–184. doi:10.1016/j.biopha.2016.01.02226898440
   PubMed Web of Science ®Google Scholar
• Mokutani Y, Uemura M, Munakata K, et al. Down-regulation of microRNA-132 is associated with poor prognosis of colorectal cancer. Ann Surg Oncol. 2016;12:23.
   Google Scholar
• Akhurst RJ, Derynck R. TGF-beta signaling in cancer-a double- edged sword. Trends Cell Biol. 2001;11(11):S44–S51.11684442
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29(2):117–129. doi:10.1038/ng1001-11711586292
   PubMed Web of Science ®Google Scholar
• Wei H, Kamat AM, Aldousari S, et al. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One. 2012;7(12):e51758. doi:10.1371/journal.pone.005175823251617
   PubMed Web of Science ®Google Scholar
• Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007;1775(1):21–62. doi:10.1016/j.bbcan.2006.06.00416904831
   PubMed Web of Science ®Google Scholar
• Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12(1):22–29.11790550
   PubMed Web of Science ®Google Scholar
• Zhang Q, Miao S, Han X, et al. MicroRNA-3619-5p suppresses bladder carcinoma progression by directly targeting β-catenin and CDK2 and activating p21. Cell Death Dis. 2018;9(10):960. doi:10.1038/s41419-018-1111-y30237499
   PubMedGoogle Scholar
• Abba M, Patil N, Leupold JH, Allgayer H. MicroRNAs from metastasis prediction to metastasis prevention? Mol Cell Oncol. 2015;3(2):e1074336. doi:10.1080/23723556.2015.107433627308596
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao K, Miao C, et al. Silencing Trim59 inhibits invasion/migration and epithelial-to-mesenchymal transition via TGF-β/smad 2/3 signaling pathway in bladder cancer cells. OncoTargets Ther. 2017;10:1503–1512. doi:10.2147/OTT.S130139
   PubMed Web of Science ®Google Scholar
• Jiang Z, Song Q, Zeng R, et al. MicroRNA-218 inhibits EMT, migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical cancer. Oncotarget. 2016;7:29. doi:10.18632/oncotarget.9850.
   Google Scholar
• Li Q, Liang X, Wang Y, et al. miR-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by down- regulating BCL2. Sci Rep. 2016;6:27157. doi:10.1038/srep2715727244080
   PubMed Web of Science ®Google Scholar
• Wang LL, Zhang XH, Zhang X, Chu JK. MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition(EMT). Eur Rev Med Pharmacol Sci. 2016;20(9):1733–1739.27212164
   PubMed Web of Science ®Google Scholar
• Li L, Xu QH, Dong YH, et al. MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells. Eur Rev Med Pharmacol Sci. 2016;20(10):2004–2010.27249598
   PubMed Web of Science ®Google Scholar